The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
To understand how Hendra virus multiplies in infected cells, we will investigate the structure of its replicative machinery. This will provide the basis for rational drug design increasing Australia’s preparedness against the emergence of Hendra-like viruses.
Systems Biology To Identify Molecular Targets For Vascular Disease Treatment (SysVasc), With A Focus On Atherosclerotic Plaque Instability
Funder
National Health and Medical Research Council
Funding Amount
$450,721.00
Summary
Heart attacks are caused by rupture of atherosclerotic deposits (plaques) in vessel walls, which results in clot formation ultimately causing vessel occlusion. In collaboration with strong European collaborators, we will use modern high-throughput technologies in a large patient cohort as well as in a newly generated mouse model to discover the causative proteins, genes and their regulators. This will allow identifying individuals at risk and developing novel therapies to prevent heart attacks.
Harnessing Lipid-reactive Immunity To Combat Mycobacterium Tuberculosis Infection
Funder
National Health and Medical Research Council
Funding Amount
$341,458.00
Summary
Critcial to the survival of Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) is its unique waxy (lipid)-rich cell wall. This proposal aims to target components of its cell wall to devlop novel therapeutic strategies. Specifically, the Australian-Singapore alliance will examine how the immune system "sees" lipid based antigens from M. tuberculosis, and then will ultimately use this information towards the devlopment of novel lipid-based vaccines.
Targeting G-quadruplex DNA As A Novel Therapeutic Strategy For Alzheimer’s And Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
Dementia is the third leading cause of death in Australia and there is an urgent need to identify new ways of treating diseases that cause dementia. Our research is focused on targeting an unusual DNA structure in Alzheimer’s and Frontotemporal dementia (FTD). We will use a precision-targeted technology to better control formation of this DNA structure in disease-causing genes, allowing us to switch off the gene and hence stop disease progression for Alzheimer’s and FTD.
Discovering Novel Molecules That Regulate Axonal Degeneration.
Funder
National Health and Medical Research Council
Funding Amount
$588,622.00
Summary
The axon is the primary signaling component of every neuron and is essential for normal function. Axonal degeneration is a key early pathological hallmark of Alzheimer’s disease. We lack a basic understanding of molecules that regulate this process. Such knowledge is essential for the development of treatments and therapies for dementia and the preservation of healthy ageing. I aim to discover the molecules that regulate axonal degeneration and study their function.
Neuronal Membranes And Connections In Dementia: Targets For Intervention
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
This research aims to understand why some people with Mild Cognitive Impairment (MCI) progress to dementia, whilst others do not. The fact that some people’s cognitive abilities can improve provides an opportunity to study the mechanisms that protect their brain cells from the degeneration associated with dementia. Understanding the cellular changes will lead to therapies that can be tested in the lab for individuals.
Dementias affect a large number of Australians each year with the number of patients expected to triple by 2050. As such, there is need to develop a better model of this debilitating disorder to provide improved treatments. Mesenchymal stem cells, are relatively easy to obtain and grow, and are able to produce the key cell types in the brain. We can use these cells to identify the processes that control the production of brain cells, which will likely provide better treatment of this disease.
Kidney Mesenchymal Stem Cells In Tubular Development, Repair And Turnover
Funder
National Health and Medical Research Council
Funding Amount
$989,141.00
Summary
In Australia, 11.3% of deaths are associated with chronic kidney disease with >$1 billion per annum spent on treating this condition. At present, only dialysis and transplantation are available to treat end stage kidney disease. We have found a kidney stem cell population in both human and mouse that can form new epithelial structures. In this project, we will investigate the normal role played by these kidney stem cells and examine whether they can contribute to kidney regeneration.
Alzheimer’s disease (AD), is the most common form of dementia, accounting for between 50-70% of all cases. There is general agreement that current treatments for AD/dementia are inadequate so new treatment strategies are desperately needed. I am addressing these challenges by developing new technologies to generate next generation treatments for AD.